94 related articles for article (PubMed ID: 19761684)
1. Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia.
Sayitoglu M; Haznedaroğlu IC; Hatirnaz O; Erbilgin Y; Aksu S; Koca E; Adiguzel C; Bayik M; Akalin I; Gülbas Z; Akay M; Unal A; Kaynar L; Ovali E; Yilmaz M; Yenerel M; Dagdas S; Ozet G; Ar C; Aydin Y; Soysal T; Durgun B; Ozcebe O; Tukun A; Ilhan O; Ozbek U
J Int Med Res; 2009; 37(4):1018-28. PubMed ID: 19761684
[TBL] [Abstract][Full Text] [Related]
2. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
3. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
[TBL] [Abstract][Full Text] [Related]
4. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
5. Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.
Vandyke K; Fitter S; Drew J; Fukumoto S; Schultz CG; Sims NA; Yeung DT; Hughes TP; Zannettino AC
J Clin Endocrinol Metab; 2013 Jan; 98(1):67-76. PubMed ID: 23144472
[TBL] [Abstract][Full Text] [Related]
6. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
[TBL] [Abstract][Full Text] [Related]
8. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
9. Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate.
Sonmez M; Akagun T; Cobanoglu U; Topbas M; Erkut N; Yilmaz M; Ovali E; Omay SB
Hematology; 2009 Aug; 14(4):220-3. PubMed ID: 19635185
[TBL] [Abstract][Full Text] [Related]
10. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
11. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
12. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
13. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
14. Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.
Einwallner E; Jaeger E; Mitterbauer-Hohendanner G; Bilban M; Simonitsch-Klupp I; Steiner I; Pernicka E; Hoermann G; Herndlhofer S; Sillaber C; Valent P; Schwarzinger I
Stem Cells Dev; 2013 Dec; 22(23):3043-51. PubMed ID: 23883175
[TBL] [Abstract][Full Text] [Related]
15. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
16. Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Kriener S; Engels K; Staib P; Griesshammer M; Waller CF; Ottmann OG; Hansmann ML
Histol Histopathol; 2004 Oct; 19(4):1277-88. PubMed ID: 15375771
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin system expression in the K562 human erythroleukaemic cell line.
Koca E; Haznedaroglu IC; Acar K; Beyazit Y; Aksu S; Misirlioglu M; Tuncer S; Sayinalp N; Ozcebe OI; Uner A
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):145-7. PubMed ID: 17907103
[TBL] [Abstract][Full Text] [Related]
20. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]